Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Day One Biopharmaceuticals (DAWN) Shares Outstanding (Weighted Average) (2022 - 2025)

Historic Shares Outstanding (Weighted Average) for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Q3 2025 value amounting to $103.4 million.

  • Day One Biopharmaceuticals' Shares Outstanding (Weighted Average) rose 699.44% to $103.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $103.4 million, marking a year-over-year increase of 699.44%. This contributed to the annual value of $93.2 million for FY2024, which is 1687.44% up from last year.
  • According to the latest figures from Q3 2025, Day One Biopharmaceuticals' Shares Outstanding (Weighted Average) is $103.4 million, which was up 699.44% from $103.1 million recorded in Q2 2025.
  • In the past 5 years, Day One Biopharmaceuticals' Shares Outstanding (Weighted Average) registered a high of $103.4 million during Q3 2025, and its lowest value of $58.4 million during Q1 2022.
  • For the 4-year period, Day One Biopharmaceuticals' Shares Outstanding (Weighted Average) averaged around $82.7 million, with its median value being $86.0 million (2023).
  • Per our database at Business Quant, Day One Biopharmaceuticals' Shares Outstanding (Weighted Average) soared by 2337.76% in 2023 and then soared by 699.44% in 2025.
  • Day One Biopharmaceuticals' Shares Outstanding (Weighted Average) (Quarter) stood at $65.5 million in 2022, then increased by 21.85% to $79.8 million in 2023, then increased by 16.87% to $93.2 million in 2024, then rose by 10.88% to $103.4 million in 2025.
  • Its last three reported values are $103.4 million in Q3 2025, $103.1 million for Q2 2025, and $102.7 million during Q1 2025.